Atezolizumab as first-line therapy for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival

被引：0
|
作者：
Marcella, E. [1 ]
Susanto, B. [1 ]
Chen, S. [1 ]
Tandiono, J. [1 ]
Tancherla, A. [1 ]
Heriyanto, R. S. [1 ]
Wijovi, F. [1 ]
Kurniawan, A. [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Tangerang, Indonesia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112P
引用
收藏
页码：S759 / S759
页数：1
相关论文
共 50 条
  • [21] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
    He, Mingfeng
    Zheng, Taihao
    Zhang, Xiaoyue
    Peng, Yuan
    Jiang, Xuan
    Huang, Yusheng
    Tan, Benxu
    Yang, Zhenzhou
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1345 - 1355
  • [22] REAL-WORLD EFFECTIVENESS AND SAFETY OF FIRST-LINE PEMBROLIZUMAB MONOTHERAPY FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Kamboj, G.
    Radotra, A.
    Barman, P.
    Dongare, S.
    Aggarwal, S.
    Rathi, H.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S398 - S398
  • [23] CLINICOPATHOLOGICAL AND MOLECULAR PREDICTIVE FACTORS OF SURVIVAL IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH FIRST-LINE IMMUNOTHERAPY WITH OR WITHOUT CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Di Federico, Alessandro
    Gelsomino, Francesco
    De Giglio, Andrea
    Sperandi, Francesca
    Melotti, Barbara
    Ardizzoni, Andrea
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A833 - A835
  • [24] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
    Mingfeng He
    Taihao Zheng
    Xiaoyue Zhang
    Yuan Peng
    Xuan Jiang
    Yusheng Huang
    Benxu Tan
    Zhenzhou Yang
    [J]. Cancer Immunology, Immunotherapy, 2022, 71 : 1345 - 1355
  • [25] The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
    Sheng, Jin
    Yang, Yunpeng
    Ma, Yuxiang
    Yang, Bijun
    Zhang, Yaxiong
    Kang, Shiyang
    Zhou, Ting
    Hong, Shaodong
    Qin, Tao
    Hu, Zhihuang
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    [J]. PLOS ONE, 2015, 10 (06):
  • [26] Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival
    Farris, M. S.
    Larkin-Kaiser, K. A.
    Scory, T.
    Boyne, D.
    Wilner, K. D.
    Pastel, M.
    Cappelleri, J. C.
    Ivanova, J. I.
    [J]. FUTURE ONCOLOGY, 2020, 16 (36) : 3107 - 3116
  • [27] Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review
    Tandiono, J.
    Chen, S.
    Marcella, E.
    Susanto, B.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S760
  • [28] An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer
    Afzal, Muhammad Zubair
    Dragnev, Konstantin H.
    Shirai, Keisuke
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [29] Survival benefit from maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer: A meta-analysis.
    Chouahnia, Kader
    Guetz, Gaetan Des
    Uzzan, Bernard
    Nicolas, Patrick
    Morere, Jean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
12345